

# Russell W Read

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10490188/publications.pdf>

Version: 2024-02-01

23  
papers

2,415  
citations

516215

16  
h-index

676716

22  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1779  
citing authors

#	ARTICLE	IF	CITATIONS
1	Complications and prognostic factors in Vogt-Koyanagi-Harada disease. American Journal of Ophthalmology, 2001, 131, 599-606.	1.7	208
2	Frequency of Distinguishing Clinical Features in Vogt-Koyanagi-Harada Disease. Ophthalmology, 2010, 117, 591-599.e1.	2.5	145
3	Histologic Basis of Variations in Retinal Pigment Epithelium Autofluorescence in Eyes with Geographic Atrophy. Ophthalmology, 2013, 120, 821-828.	2.5	131
4	Neoplastic Masquerade Syndromes. Survey of Ophthalmology, 2002, 47, 81-124.	1.7	120
5	Subretinal Pigment Epithelial Deposition of Drusen Components Including Hydroxyapatite in a Primary Cell Culture Model. , 2017, 58, 708.		105
6	Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease. American Journal of Ophthalmology, 2006, 142, 119-124.	1.7	101
7	Clinical mini-review: systemic lupus erythematosus and the eye. Ocular Immunology and Inflammation, 2004, 12, 87-99.	1.0	91
8	Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy. Experimental Eye Research, 2011, 93, 413-423.	1.2	91
9	Vogt-Koyanagi-Harada disease. Ophthalmology Clinics of North America, 2002, 15, 333-341.	1.8	74
10	Distribution of complement anaphylatoxin receptors and membrane-bound regulators in normal human retina. Experimental Eye Research, 2006, 83, 834-840.	1.2	69
11	Uveitis: Advances in understanding of pathogenesis and treatment. Current Rheumatology Reports, 2006, 8, 260-266.	2.1	60
12	Occlusive Retinal Vasculitis Associated With Systemic Lupus Erythematosus. JAMA Ophthalmology, 2000, 118, 588.	2.6	54
13	Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. Experimental Eye Research, 2006, 82, 389-394.	1.2	53
14	Utility of existing Vogt-Koyanagi-Harada syndrome diagnostic criteria at initial evaluation of the individual patient: a retrospective analysis. Ocular Immunology and Inflammation, 2000, 8, 227-234.	1.0	36
15	Splendore-Hoeppli Phenomenon in the Conjunctiva: Immunohistochemical Analysis. American Journal of Ophthalmology, 2005, 140, 262.e1-262.e7.	1.7	34
16	Evaluation of the role of human retinal vascular endothelial cells in the pathogenesis of CMV retinitis. Ocular Immunology and Inflammation, 1999, 7, 139-146.	1.0	19
17	Rehabilitation Referral for Patients With Irreversible Vision Impairment Seen in a Public Safety-Net Eye Clinic. JAMA Ophthalmology, 2018, 136, 400.	1.4	15
18	Intraocular Pressure in a Somali Population Living in the United States. Journal of Glaucoma, 2003, 12, 365-369.	0.8	6

#	ARTICLE	IF	CITATIONS
19	The complement anaphylatoxin receptors are not required for the development of experimental autoimmune uveitis. <i>Journal of Neuroimmunology</i> , 2013, 264, 127-129.	1.1	6
20	Experimental autoimmune uveitis in the C57BL/6 mouse. <i>Experimental Eye Research</i> , 2006, 83, 229-230.	1.2	4
21	Magnetic Resonance Imaging of Choroidal Inflammation in Vogt-Koyanagi-Harada Disease. <i>Journal of Neuro-Ophthalmology</i> , 2004, 24, 295-296.	0.4	3
22	Peroxynitrite formation in the orbit of diabetics with rhinocerebral mucormycosis. <i>Ocular Immunology and Inflammation</i> , 2000, 8, 169-175.	1.0	2
23	VOGT-KOYANAGI-HARADA DISEASE 364.24 (Harada's Disease; Uveomeningitis). , 2008, , 303-305.		0